Saturday, June 17, 2017 12:04:23 AM
I think the long time it has taken reflects the learning curve for management, the increasingly ambitious goals, and the developing marketplace.
One can only know the optimum allocation of funds to R&D vs marketing at a given time if one is inside the company.
The little guy's responsibility in this type of investment is to objectively weigh the risk vs reward. The risks are substantial. Dilution is to be expected. The real question is what that dilution buys. As a little guy, I expect to profit significantly by this investment, but my eyes are wide open and I know that I might not.
I imagine a person used to investing in established companies would be uncomfortable in this position.
Recent SDCH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 09:54:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 09:48:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 12:05:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 12:00:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 08:57:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 08:55:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 08:53:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 08:51:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 12:15:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/05/2024 01:00:19 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 12/28/2023 10:25:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/27/2023 10:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:00:16 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 12/21/2023 02:09:12 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 12/11/2023 10:01:10 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 12/04/2023 03:58:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 10:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:13:59 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 11/03/2023 02:09:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:54:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:52:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM